Filing Analysis
Sutro Biopharma announced topline results from the dose-optimization portion (Part 1) of its REFRΞ±ME-O1 clinical trial for luvelta, an ADC targeting platinum-resistant ovarian cancer. The data showed a 32% objective response rate and a 96% disease control rate in the 5.2 mg/kg dosing group.
π© Red Flags
- Clinical stage risk: Results are from a small dose-optimization cohort (N=25), which may not fully predict outcomes in the larger Part 2 registrational trial.
- Safety signal: 32% incidence of Grade 3 or higher neutropenia.
π Key Facts
- Trial: REFRΞ±ME-O1 (Part 1) dose-optimization portion for luvelta in platinum-resistant ovarian cancer (PROC).
- Objective Response Rate (ORR): 32% in the 5.2 mg/kg group (N=25).
- Disease Control Rate (DCR): 96% in the 5.2 mg/kg group.
- Safety: Grade 3 or higher neutropenia occurred in 32% of patients; no febrile neutropenia reported.
- Patient Profile: Approximately 50% of treated patients were ineligible for currently approved FRΞ±-targeting ADCs; 88% had prior bevacizumab treatment.
- Next Steps: REFRΞ±ME-O1 (Part 2) is an ongoing global registrational trial enrolling ~500 patients comparing luvelta to investigator's choice of chemotherapy.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
π Key Facts
- Report date: November 13, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release regarding financial results (Exhibit 99.1)
- Signed by Edward Albini, Chief Financial Officer
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notification of the release of quarterly earnings data.
π Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Sutro Biopharma, Inc. announced the appointment of Sukhi Jagpal to its Board of Directors as a Class III director and member of the Audit Committee.
π Key Facts
- Sukhi Jagpal appointed as Class III director effective August 8, 2024.
- Jagpal will join the Audit Committee effective August 15, 2024.
- Compensation includes a pro rata portion of a $40,000 annual director retainer and a $10,000 annual Audit Committee retainer.
- Granted stock option for 35,000 shares vesting monthly over three years.
- Granted stock option for 28,959 shares vesting monthly until the 2025 annual meeting of shareholders.
Sutro Biopharma, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the election of two Class III directors and the ratification of Ernst & Young LLP as the company's independent auditor.
π Key Facts
- Held 2024 Annual Meeting of Stockholders on June 6, 2024.
- Elected Joseph M. Lobacki to a three-year term (expires 2027).
- Elected Daniel H. Petree to a three-year term (expires 2027).
- Ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Approved non-binding advisory compensation ('Say on Pay') for named executive officers.
- Approved amendment to the 2018 Employee Stock Purchase Plan (ESPP) to increase share limits and make clarifying revisions.
Sutro Biopharma, Inc. filed an 8-K to announce its quarterly financial results for the period ended March 31, 2024.
π Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Filing date: May 13, 2024.
- The financial results were released via press release attached as Exhibit 99.1.
Sutro Biopharma, Inc. entered into an underwriting agreement to issue and sell 14,478,764 shares of common stock at $5.18 per share. The offering aims to raise approximately $75 million in gross proceeds for general corporate purposes, including R&D and clinical development.
π© Red Flags
- Significant dilution for existing shareholders due to the issuance of over 14 million new shares.
π Key Facts
- Offering size: 14,478,764 shares of common stock.
- Offering price: $5.18 per share.
- Estimated gross proceeds: Approximately $75.0 million.
- Underwriter: BofA Securities, Inc.
- Expected closing date: April 4, 2024.
- Use of proceeds: Research, clinical/process development, manufacturing, working capital, and potential acquisitions.
Sutro Biopharma entered into an exclusive license agreement with Ipsen Pharma SAS for the development and commercialization of STRO-003. The deal includes a significant upfront cash payment and a strategic equity investment from an Ipsen affiliate.
π© Red Flags
- Ipsen retains the right to terminate the agreement for convenience with 60 days' notice, which limits Sutro's long-term control over the asset.
- The equity issuance is a private placement (unregistered sale) involving an affiliate of the licensee.
π Key Facts
- Exclusive License Agreement signed March 29, 2024, with Ipsen Pharma SAS regarding STRO-003.
- $50 million upfront license fee payable within 30 days of the effective date.
- Ipsen Biopharmaceuticals, Inc. (affiliate) to purchase 4,827,373 shares for $25 million at a 17% premium to the 20-day VWAP.
- Potential milestone payments: up to $7 million cash and $10 million in additional shares upon specific developmental milestones.
- Total potential future value includes up to $447 million in development/regulatory milestones and up to $360 million in sales milestones.
- Royalty payments range from low double-digit to mid-teen percentages of annual net sales.
Sutro Biopharma, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the release of their annual earnings press release.
π Key Facts
- Report date: March 25, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the official press release of financial results.
- Information under Item 2.02 is furnished but not considered 'filed' for liability purposes.
Sutro Biopharma, Inc. has filed a prospectus supplement to its existing 2023 Form S-3 shelf registration statement to increase the aggregate dollar amount of shares available for sale by $100,000,000.
π© Red Flags
- Significant increase in share availability ($100M) suggests a need for immediate liquidity or capital to fund operations, common in pre-revenue biotech firms.
π Key Facts
- Increased the aggregate dollar amount of shares available under the Sales Agreement by $100,000,000 via a prospectus supplement filed on February 9, 2024.
- The company has previously sold an aggregate of $70,725,847.70 in shares through its 2021 Form S-3 shelf registration statement.
- As of the filing date, remaining capacity under the 2021 S-3 is $29,274,152.30; the new supplement adds $100,000,000 in capacity.
- The sales agent for these transactions is Jefferies LLC.
Sutro Biopharma reported its preliminary cash position as of December 31, 2023, and provided clinical updates for its lead ADC candidate, luvelta. The company maintains a significant cash runway extending into the second half of 2025.
π© Red Flags
- Financial data is preliminary, unaudited, and subject to change upon final audit.
π Key Facts
- Reported approximately $333 million in cash, cash equivalents, and marketable securities as of Dec 31, 2023.
- Held ~0.7 million shares of Vaxcyte common stock with an estimated fair value of ~$42 million.
- Cash runway is expected to fund operations into the second half of 2025.
- Luvelta REFRΞ±ME-O1 trial (ovarian cancer) expects Part 1 completion in H1 2024.
- Planned IND submission for non-small cell lung cancer (NSCLC) in H1 2024.